3 Stocks To Benefit From A US Rate Hike: AstraZeneca plc, BHP Billiton plc And Unilever plc

AstraZeneca plc (LON:AZN), BHP Billiton plc (LON:BLT) and Unilever plc (LON:ULVR) can all benefit…

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Next month could deliver a shock to the system if the US Federal Reserve really does hike interest rates for the first time in nearly a decade.

The last time the Fed actually lifted rates was in June 2006, so for many newbie investors this will be unknown territory. It may knock markets off course (as it did last time) but there will be some positives for UK investors. High interest rates mean a stronger dollar, especially if the Fed hikes rates twice this year, as many expect.

This is good news for Britain’s with shares in FTSE 100 companies that pay their dividends in dollars, whose income will look even more attractive when converted into relatively weak sterling. The last 12 months have already been good news for dollar dividends, with the pound falling to $1.55 today, against $1.66 one year ago, a drop of 6.6%. Now there could be more to come.

Here are three companies that should benefit.

AstraZeneca

Pharmaceutical giant AstraZeneca (LSE: AZN) currently yields 4.20% and the money hits your bank account in dollars, which means it could look even juicier next month.

The stock has had a tough time lately, however, falling 6.8% in the last six months, worse than the 5% drop in the FTSE 100. Q2 core operating profits fell 4% to £3.62 bn, as management focuses on investing heavily in its drugs pipeline. Things could get tougher with treatments Crestor and Nexium both coming off patent in the next couple of years, as they accounted for a third of group sales last year.

AZN’s future will largely depend on whether chief executive Pascal Soriot is right to put his faith in the company’s new generation of blockbuster cancer drugs, which he hopes will deliver $45bn-plus revenues by 2023. But it is nice to see a FTSE 100 company investing hard for the future, given so much short-termism elsewhere. And you get a dollar-driven dividend while you wait.

BHP Billiton

Investors in troubled mining giant BHP Billiton (LSE: BLT) need some good news, with the stock down almost 40% in the last year on falling demand from China. Personally, I think China will get worse before things get better, although there are signs that the authorities’ latest stimulus this package will keep the growth story rattling along for a few years more.

What is bad news for BHP Billiton’s share price is good news for income investors, with the stock now yielding 6.39%. A stronger dollar would give a further real-terms boost to UK investors.

BHP Billiton is now dividend dynamite, although unless they are reversed, falling metals prices (iron ore now trades at $56 a tonne against $140 in January last year) must eventually force management to cut the payout. The board remains committed to the dividend from now, but expect rumblings ahead.

Unilever

Household goods giant Unilever (LSE: ULVR) is much admired by investors but its success has a downside: it has historically traded at more than 20 times earnings and yields as low as 2.5%.

Recent share price slippage has improved both figures, with the price/earnings ratio at a relatively (for Unilever) affordable 17 times, and the yield at 3.22%. A dollar surge could make that yield a little more rewarding.

Many investors backed Unilever as a safe way to play China and emerging markets, and sales from this source are still growing at around 6.5%, although the days of double-digit growth are over. Worryingly, European sales are falling.

But Unilever has delivered the goods from more than 20 years and at today’s price long-term investors should still clean up.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

100%+ earnings growth and a P/E of 8.5? Could this be a once-in-a-decade stock market gift for value investors?

As the UK stock market makes a go at a recovery, Mark Hartley identifies one FTSE 250 stock that could…

Read more »

Investing Articles

Greggs shares are up 90% in a decade. What could the next decade bring?

Mark Hartley remains optimistic about his Greggs shares, citing long-term growth. But could they still offer an opportunity for value…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

5 steps towards a Stocks & Shares ISA worth £1m

Millions of Britons are missing out on wealth creation because they're not following these steps. Dr James Fox details how…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Is now a good time to start investing in the wealth-building stock market?

The stock market is a battle-hardened builder of wealth long term. But with risks mounting, is now a good time…

Read more »

Investing Articles

£10,000 invested in red-hot Tesco shares just 1 week ago is now worth…

Harvey Jones is impressed by how well Tesco shares have defied recent stock market volatility. So can this FTSE 100…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

See the income from investing a £20k ISA in this UK stock before it goes ex-dividend on 9 April

Harvey Jones says this UK stock offers one of the highest yields on the FTSE 100. Investors need to act…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

What’s going on with the AstraZeneca share price now?

Dr James Fox explores the recent movements in the AstraZeneca share price and evaluates whether it's still a good long-term…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This S&P 500 stock is down 30% and the CEO just bought $10m worth of shares

Insiders only buy a stock for one reason – they expect its price to go up. So, this S&P 500…

Read more »